|
THIS MONTH IN SKIN CANCER
UCLA researchers have developed a methodology to predict whether advanced melanoma patients will or will not respond to the breakthrough drug pembrolizumab (Keytruda, Merck). » What the algorithm reveals |
ADVERTISEMENT
The 11th Annual Maui Derm for Dermatologists 2015
will be held January 26 - Friday, January 30, 2015 in the intimate and beautiful setting of the Grand Wailea in Wailea, Maui.
 Register now
|
|
Evidence from ongoing trials will reveal the optimal approach to combining immune therapy and molecularly targeted therapy in the treatment of malignant melanoma, according to a presenter here at the 8th Canadian melanoma conference. » Read more |
|
Although melanoma and non-melanoma skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are more prevalent in Caucasian skin, patients with darker Fitzpatrick Skin Types are also at risk of developing skin cancers, underscoring the importance for this patient population to practice appropriate photoprotection. » Read more
|
|
Gene expression profiling with a commercially available test (DecisionDx-Melanoma, Castle Biosciences) provides useful prognostic information for patients with high-risk cutaneous melanoma who undergo sentinel lymph node (SLN) biopsy, and particularly for those found to be node-negative, according to a study presented at the annual meeting of the American Society for Clinical Oncology. » Read more
|
|
|
Like
Tweet
